Untreatable tuberculosis: Is surgery the answer?

European Respiratory Journal

Volumn 45, Issue 3, 2015, Pages 577-582

  Dara, Masoud ^a   Sotgiu, Giovanni ^b   Zaleskis, Richard ^a   Migliori, Giovanni Battista ^c  

^a WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^b UNIVERSITY OF SASSARI   (Italy)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BEDAQUILINE; CAPREOMYCIN; DELAMANID; ISONIAZID; KANAMYCIN; LINEZOLID; MEROPENEM; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL PNEUMOTHORAX; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HUMAN; LUNG LOBECTOMY; LUNG RESECTION; LUNG SURGERY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SURGICAL TECHNIQUE; THORAX DRAINAGE; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUBERCULOSIS; TUBERCULOUS SPONDYLITIS; HEALTH; MULTIMODALITY CANCER THERAPY; PREVALENCE; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; GLOBAL HEALTH; HUMANS; PNEUMOTHORAX, ARTIFICIAL; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84923872569     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00229514     Document Type: Article

References (30)

1. World Health Organization. Global Tuberculosis report 2014. Document WHO/HTM/TB/2014.08. Geneva, WHO, 2014.
2. Glaziou P, Falzon D, Floyd K, et al. Global epidemiology of tuberculosis. Semin Respir Crit Care Med 2013; 34: 3-16.
3. Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J 2015; 45: 150-160.
4. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
5. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
6. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. Document WHO/HTM/TB/2011.6. Geneva, World Health Organization, 2011.
8. Migliori GB, Sotgiu G. Treatment of tuberculosis: have we turned the corner? Lancet 2012; 380: 955-957.
9. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
10. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
11. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
12. Sotgiu G, Migliori GB. Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther 2014 [In press DOI: 10.1016/j.pupt.2014.04.006].
13. Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J 2014; 43: 1763-1775.
14. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
15. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools. Outcome of an ERS multi-sectoral Consultation, Rome, July 3rd, 2014. Eur Respir J 2014; 44: 1412-1417.
16. Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015; 45: 554-557.
17. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
18. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur Respir J 2011; 37: 978-981.
19. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
20. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
21. De Palma M, ed. La Tuberculosi in Italia dal 1882 al 1950 [Tuberculosis in Italy from 1882 to 1950]. Milan, Federazione Italiana contro le Malattie Polmonari Sociali e la Tubercolosi, 2003.
22. Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 6-16.
23. The role of surgery in the treatment of pulmonary TB and multidrug- and extensively drug-resistant TB. Copenhagen, WHO Regional Office for Europe, 2014.
24. Dara M, Kluge H. Consolidated action plan to prevent and combat M/XDR-TB in the WHO European Region 2011-2015. Copenhagen, WHO Regional Office for Europe, 2011.
25. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
26. Dye C, Glaziou P, Floyd K, et al. Prospects for tuberculosis elimination. Annu Rev Public Health 2013; 34: 271-286.
27. Sotgiu G, Mauch V, Migliori GB, et al. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. Eur Respir J 2014; 43: 1563-1566.
28. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
29. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
30. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015 [In press DOI: 10.1183/09031936.00214014].